← All trials
NCT05948566
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2024
- Primary completion
- Jul 31, 2027
- Completion date
- Dec 31, 2027
- First posted
- Jul 17, 2023
- Last posted
- Nov 18, 2023
- Enrollment
- 300
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Translational Sciences, Inc.Lead sponsor
- Medical University of South CarolinaCollaborator
- University of ArizonaCollaborator
- University of CincinnatiCollaborator
- National Institute of Neurological Disorders and Stroke (NINDS)Collaborator
- University of CincinnatiOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.